Terazosin Hydrochloride
Product Images NDC 24689-961

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Terazosin Hydrochloride (NDC 24689-961). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apnar Pharma Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg-100ct (10mg 100ct)

Label for Terazosin Hydrochloride Capsules, USP 10 mg, manufactured by Apnar Pharma LP. This label indicates 100 capsules per container with storage instructions and a note to dispense with patient information. The label features the Apnar Pharma logo and an NDC barcode.*

FDA Label Image

1mg-100ct (1mg 100ct)

Label for Terazosin Capsules, USP 1 mg by Apnar Pharma LP. The label includes the NDC 24689-792-01, states prescription use only, and indicates each capsule contains 1 mg terazosin hydrochloride. The package contains 100 capsules and features storage instructions, safety warnings, and a barcode.*

FDA Label Image

2mg-100ct (2mg 100ct)

Terazosin Capsules, USP 2 mg capsule label showing the product name, strength, and quantity of 100 capsules. The label includes NDC 24689-855-01 and states the active ingredient terazosin hydrochloride equivalent to 2 mg terazosin per capsule. It is manufactured for Apnar Pharma LP, Chino, CA. The label also provides storage instructions and a barcode.*

FDA Label Image

5mg-100ct (5mg 100ct)

Label for Terazosin Capsules, USP 5 mg by Apnar Pharma LP. The label states each capsule contains Terazosin hydrochloride equivalent to 5 mg Terazosin. The package contains 100 capsules. Storage instructions and a pharmacist notice to dispense with a patient information sheet are included.*

FDA Label Image

Terazosinhydrochloridechemicalstructure (Chemicalstructure)

Chemical structure of Terazosin Hydrochloride, showing the molecular arrangement including aromatic rings, methoxy groups, piperazine ring, carbamate linkage, and hydrochloride component.*

FDA Label Image

Figure1 (Figure1)

Two line graphs comparing Terazosin and placebo groups over 3 months. The left graph shows mean change in total symptom score from baseline, with Terazosin showing a greater decrease. The right graph shows mean increase in peak flow rate (mL/sec) from baseline, with Terazosin demonstrating larger increases over time. Sample sizes are 54-55 per group.*

FDA Label Image

Figure2 (Figure2)

Line graph presenting mean change from baseline over a 30-month period. The vertical axis represents mean change values, while the horizontal axis represents time in months. Data points show a decreasing trend in mean change, with several marked statistically significant points denoted by asterisks.*

FDA Label Image

Figure3 (Figure3)

A line graph showing the mean change from baseline in mL/sec over a 30-month period. Data points are plotted monthly, showing an increase reaching a peak between months 18 and 21, followed by a slight decline towards month 30. Error bars indicate variability at each time point.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.